查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809637

家族性腺瘤息肉症治疗市场（依治疗类型、给药途径、通路、最终用户和适应症）－2025-2030 年全球预测

Familial Adenomatous Polyposis Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, End User, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

家族性腺瘤息肉症治疗市场预计到 2024 年将达到 12 亿美元，到 2025 年将达到 12.9 亿美元，到 2030 年将达到 18.6 亿美元，复合年增长率为 7.47%。

主要市场统计数据
基准年2024年 12亿美元
预计2025年 12.9亿美元
预计2030年 18.6亿美元
复合年增长率（%） 7.47%

基因突破和综合护理模式将塑造家族性腺瘤息肉症治疗中患者管理的未来

家族性腺瘤息肉症(FAP) 是一种遗传性疾病，会导致结肠和直肠中出现数百至数千个腺瘤性息肉，如果不及时治疗，几乎肯定会发展为恶性肿瘤。本文将深入探讨 FAP 的遗传基础：APC 抑癌基因突变会启动早期息肉的形成，最终导致大肠直肠癌的进展。鑑于早期病变无症状且癌症风险较高，早期诊断和风险评估的重要性不容忽视。

揭示由创新基因治疗技术和以患者为中心的方法推动的家族性腺瘤息肉症治疗的变革性转变

过去十年，一系列科学突破和技术创新彻底改变了家族性腹痛（FAP）的治疗模式。其中，精准医疗方法占据了主导地位，该方法利用基因图谱对患者风险进行分层，并相应地制定治疗方法。 CRISPR/Cas系统等基因编辑技术已从临床前模型发展到早期人体临床试验，并有望从源头直接修正致病性APC突变。同时，单株抗体设计和标靶递送系统的进步，带来了对肿瘤路径特异性增强的生物化合物，从而减少了脱靶效应并提高了耐受性。

2025 年美国关税对家族性腺瘤息肉症：获取动态和成本结构分析

美国将于2025年对进口医疗设备和药品成分征收新关税，这给家庭和行动障碍（FAP）治疗供应链带来了多方面的压力。影响内视镜系统、专用内视镜配件和诊断剂的关税增加了医疗保健提供者的采购成本，导致公共和私营部门的预算紧缩。非类固醇消炎剂和生物製药製剂也受到类似影响，导致製造成本增加，而这些成本可能会在某些报销框架下转嫁给付款人和患者。

治疗方式、给药途径、通路、最终用户资料和具体适应症的关键细分洞察

在对治疗类型进行详细细分后，可以发现针对不同疾病阶段和患者特征的多种治疗方法。联合治疗方案整合多种药物以协同抑制腺瘤生长，而内视镜监测则透过大肠镜检查和乙状结肠镜检查提供有针对性的介入措施。在药物治疗中，生物治疗方法包括旨在纠正 APC 突变的先进基因治疗平台，以及针对息肉发展中涉及的关键讯号通路的单株抗体。非类固醇消炎剂（分为选择性 COX-2 抑制剂和传统非选择性 NSAID）透过调节与肿瘤转化相关的发炎连锁提供额外的化学预防益处。对于有广泛息肉的患者，手术介入仍然是一个重要选择，手术范围从全髂骨、迴肠直肠吻合术到肛门直肠切除术，每种手术在功能结果和生活品质方面都有不同的权衡。

确定影响美洲、欧洲、中东和非洲以及亚太地区遗传性息肉症治疗采用的关键区域动态

区域分析显示，美洲、欧洲、中东和非洲 (EMEA) 以及亚太地区呈现出不同的应用模式和策略重点。在美洲，强大的研究基础设施和完善的报销框架支持先进内视镜技术和生物目标疗法的早期应用。北美领先的学术中心正在主导基因编辑方法的临床试验，偏远地区的远距远端医疗倡议正在改善监测推广和依从性监测。

重点介绍在家族性腺瘤息肉症治疗生态系统中推动创新伙伴关係和竞争地位的关键产业参与者

FAP 治疗产业格局涉及多元化的产业相关人员，包括生物製药创新者、医疗设备製造商和专业服务供应商。领先的生物技术公司已透过利用病毒和非病毒递送载体靶向 APC 基因校正的早期研究，推进了基因治疗候选药物的研发。现有製药公司持续优化其单株抗体产品线，专注于调节 Wnt 讯号传导和减少息肉负担的新型抗原表位。非选择性和 COX-2 选择性 NSAID 开发人员正在评估旨在改善胃肠道耐受性和减少全身副作用的下一代製剂。

向行业领导者提出可行的建议，以改善家族性腺瘤息肉症的治疗机会并提高患者的治疗效果

为了抓住家族性腹膜炎 (FAP) 治疗领域的新兴机会，产业领导者应优先投资先进的基因编辑平台和伴随诊断技术，以实现精准的患者分层。透过发展国内製造能力和替代采购协议来增强供应链韧性，将减轻外部关税压力对关键设备和试剂的影响。同时，与付款人建立基于价值的合作模式，将使报销奖励与患者疗效而非手术量挂钩，从而促进高成本生技药品和基因疗法的永续应用。

家族性腺瘤息肉症治疗研究的严格调查方法的详细信息，包括资料来源框架和检验过程

本报告的调查方法结合了全面的二手资料和一手资料研究，以确保研究的完整性和深度。二手资料研究广泛查阅了同行评审文献、主要胃肠病学和肿瘤学协会发布的临床指南、监管备案文件和专利资料库。市场相关情报与政策分析、贸易报告和政府出版刊物进行了交叉检验，以了解更广泛的经济和监管背景。

彙编家族性腺瘤息肉症治疗的策略见解，以指南相关人员推进治疗创新和患者照护

本执行摘要提炼了家族性腺瘤息肉症治疗领域深入研究的关键见解。从基因编辑的突破到生物和药物疗法的增强，精准医疗的进步正在彻底改变临床实践，而内视镜技术和数位健康整合的改进则正在增强检测、监测和患者参与度。 2025年的关税格局凸显了供应链弹性和策略性采购的必要性，以维持治疗的可负担性和连续性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 一种针对家族性腺瘤息肉症中APC基因突变进行标靶抑制的新型基因编辑方法
  • 内视镜监测技术在早期发现FAP患者息肉的进展
  • COX-2抑制剂与EGFR抑制剂联合治疗治疗FAP的临床进展
  • 孤儿药资格认定对新型 FAP 治疗药物开发平臺的监管影响
  • 在 FAP 护理中整合预测性基因分析和个人化化学预防策略
  • FAP患者微创结直肠切除术的扩展及术后生活品质结局调查
  • 生物标记主导的临床试验的出现，评估了 FAP 患者群体中的标靶小分子疗法
  • 用于即时评估FAP患者术后復发风险的数位健康监测平台
  • 全球 FAP 市场中用于减少息肉负担的下一代 NSAID 的取得和采用趋势
  • 生技公司与学术机构建立策略伙伴关係，加速 FAP 治疗的转化研究

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章家族性腺瘤息肉症症治疗市场（依治疗类型）

  • 联合治疗
  • 内视镜监测
    • 大肠镜检查
    • 乙状结肠镜检查
  • 药物治疗
    • 生物製药
      • 基因治疗
      • 单株抗体
    • 非类固醇消炎剂
      • COX-2抑制剂
      • 非选择性非类固醇抗发炎药
  • 外科手术干预
    • 切除术
    • 髂骨吻合术
    • 切除术

第九章家族性腺瘤息肉症症治疗市场（依给药途径）

  • 静脉
  • 口服
  • 皮下

第 10 章家族性腺瘤息肉症症治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章家族性腺瘤息肉症症治疗市场（依最终使用者）

  • 居家护理
  • 医院
  • 专科诊所

第 12 章家族性腺瘤息肉症症治疗市场（依适应症）

  • 轻度FAP
  • 典型的 FAP

13.美洲家族性腺瘤息肉症症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲家族性腺瘤息肉症症治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太家族性腺瘤息肉症症治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Eloxx Pharmaceuticals, Inc.
    • Emtora Biosciences
    • KD Pharma Group
    • Biodexa Pharmaceuticals PLC
    • Thermo Fisher Scientific Inc.
    • Olympus Corporation
    • FUJIFILM Holdings Corporation
    • Pentax Ricoh Imaging Company, Ltd.
    • Medtronic plc
    • Siemens Healthcare Private Limited
    • Bayer Corporation
    • Boston Scientific Corporation
    • Parabilis Medicines

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-6B0EA0797510

The Familial Adenomatous Polyposis Treatment Market was valued at USD 1.20 billion in 2024 and is projected to grow to USD 1.29 billion in 2025, with a CAGR of 7.47%, reaching USD 1.86 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.29 billion
Forecast Year [2030] USD 1.86 billion
CAGR (%) 7.47%

Charting the Evolution of Familial Adenomatous Polyposis Treatment Fueled by Genetic Breakthroughs and Integrated Care Models Shaping Future Patient Management

Familial Adenomatous Polyposis (FAP) emerges as a hereditary condition marked by the development of hundreds to thousands of adenomatous polyps along the colon and rectum, possessing a near certainty of malignancy if unaddressed. This introduction delves into the genetic underpinnings of FAP, where mutations in the APC tumor suppressor gene initiate early polyp formation and drive progression toward colorectal cancer. The imperatives of early diagnosis and risk assessment cannot be overstated given the asymptomatic nature of initial lesions and the elevated cancer risk profile.

Over recent decades, a spectrum of interventions has evolved to mitigate disease progression and improve long term outcomes. Endoscopic surveillance techniques such as colonoscopy and sigmoidoscopy have established themselves as frontline measures to detect and remove adenomas before malignancy ensues. Pharmacologic therapies, encompassing both biologic agents and nonsteroidal anti-inflammatory drugs, have demonstrated success in polyp reduction and delay of surgical intervention.

Surgical interventions remain a cornerstone for patients at high risk or with extensive polyp burden, with options ranging from colectomy to ileorectal anastomosis and proctocolectomy. In parallel, combination approaches leveraging pharmacologic suppression and endoscopic monitoring have emerged as integrated care pathways. Patient-centric models have begun to incorporate digital health solutions that facilitate remote monitoring and adherence tracking, enabling a more proactive management approach. As research advances, next generation gene therapies and monoclonal antibodies promise to redefine treatment paradigms. The following sections will examine how these developments, alongside regulatory shifts and economic factors, are influencing the direction of FAP treatment and shaping strategic priorities for stakeholders across the healthcare ecosystem.

Illuminating Transformative Shifts in Familial Adenomatous Polyposis Treatment Driven by Innovative Gene Therapies Techniques and Patient-Centric Approaches

Over the past decade, the FAP treatment landscape has been fundamentally reshaped by a confluence of scientific breakthroughs and technological innovations. At the forefront are precision medicine approaches that leverage genetic profiling to stratify patient risk and tailor therapeutic regimens accordingly. Gene editing technologies such as CRISPR/Cas systems are advancing from preclinical models toward early human trials, offering the prospect of directly correcting pathogenic APC mutations at their source. Concurrently, advances in monoclonal antibody design and targeted delivery systems are yielding biologic compounds with enhanced specificity for neoplastic pathways, reducing off target effects and improving tolerability.

Endoscopic techniques have also undergone significant refinement, with high definition imaging and virtual chromoendoscopy enhancing polyp detection rates, while minimally invasive instruments facilitate more efficient resections. Integration of artificial intelligence and machine learning into image analysis is accelerating diagnostic accuracy and procedural efficiency. Digital health platforms are enabling continuous patient monitoring and real time data capture, fostering agile responses to treatment responses and adherence challenges.

These developments have collectively shifted FAP management from reactive polypectomy toward proactive disease interception, emphasizing early molecular intervention and personalized surveillance intervals. The emergence of combination protocols blending systemic pharmacotherapies with precision endoscopy is redefining standard of care, driving improved clinical outcomes and setting new benchmarks for long term disease control.

Regulatory frameworks have also adapted to expedite review of breakthrough therapies, with numerous expedited pathways enabling faster patient access to high potential interventions. Funding initiatives by public and private entities are accelerating early stage research, fostering collaborations that bridge academic discovery with commercial development. As these shifts coalesce, the FAP treatment arena is poised for a new era of innovation that harmonizes clinical excellence with operational agility.

Analyzing the Comprehensive Effects of 2025 United States Tariffs on Familial Adenomatous Polyposis Treatment Supply Chains Access Dynamics and Cost Structures

In 2025, newly enacted tariff measures imposed by the United States on imported medical equipment and pharmaceutical components have exerted multifaceted pressures on the FAP treatment supply chain. Tariffs affecting endoscopy systems, specialized endoscopic accessories, and diagnostic reagents have translated into higher acquisition costs for healthcare providers, challenging budgets in both public and private sectors. Pharmaceutical ingredients for nonsteroidal anti-inflammatory drugs and biologics have similarly been impacted, leading to increased production expenses that may be passed along to payers and patients under certain reimbursement frameworks.

These cumulative effects have prompted institutions to reassess procurement strategies, prioritizing suppliers with domestic manufacturing capabilities or tariff exempt status. Some clinical networks are exploring regional partnerships to establish shared warehousing and distribution hubs, mitigating the inflationary impact of cross border levies. Moreover, the anticipated cost headwinds have intensified negotiations with payers to secure value based contracts that align therapeutic reimbursement with clinical outcomes, rather than volume of procedures.

Clinicians and administrators are also evaluating the viability of alternative pharmacologic formulations that rely on locally sourced active compounds to maintain treatment affordability. While these adaptations have helped stabilize operations, persistent tariff uncertainty complicates long term planning and may hinder the adoption of next generation gene therapies that depend on specialized import components.

Patients have felt the downstream effects of these tariff driven cost shifts, encountering higher out of pocket expenses under certain insurance benefit designs. Delays in equipment replacement cycles have in some cases resulted in longer scheduling lead times for endoscopic evaluations, presenting risks for patients awaiting surveillance procedures. To safeguard patient adherence and clinical outcomes, some providers are exploring patient assistance programs and outcome based payment models that distribute financial risk and promote affordability.

Revealing Critical Segmentation Insights Across Treatment Modalities Administration Routes Distribution Channels End User Profiles and Specific Indications

An in-depth examination of treatment type segmentation reveals a diverse therapeutic arsenal tailored to distinct disease stages and patient profiles. Combination therapy protocols integrate multiple pharmacologic agents to synergistically inhibit adenoma growth, while endoscopic surveillance offers targeted interventions through colonoscopy and sigmoidoscopy procedures. Within pharmacologic therapy, biologic modalities encompass advanced gene therapy platforms designed to correct APC mutations, alongside monoclonal antibodies that target key signaling pathways implicated in polyp development. Nonsteroidal anti-inflammatory drugs, subdivided into selective COX-2 inhibitors and traditional nonselective NSAIDs, provide additional chemopreventive benefits by modulating inflammatory cascades associated with neoplastic transformation. Surgical intervention remains a critical option for individuals with extensive polyp burden, with procedures ranging from total colectomy to ileorectal anastomosis and proctocolectomy, each offering distinct trade-offs in terms of functional outcomes and quality of life.

Route of administration further differentiates therapeutic choices, with intravenous infusions employed for certain biologic agents, oral formulations enabling outpatient accessibility for chemopreventive drugs, and subcutaneous injections serving as a convenient delivery method for selected monoclonal therapies. Distribution channel dynamics influence treatment acquisition, as hospital pharmacies maintain institutional inventories for inpatient and outpatient care, online pharmacies offer streamlined ordering and home delivery, and retail pharmacies support community-based dispensing. End users span home care settings that facilitate patient self-administration under remote supervision, hospitals that deliver complex procedural and pharmacologic regimens, and specialty clinics focusing on advanced diagnostics and interventional strategies. Finally, indication specificities distinguish between attenuated FAP presentations, characterized by fewer polyps and later onset, and classic FAP profiles with early, aggressive polyp proliferation, guiding tailored therapeutic pathways across the patient journey.

Illuminating Pivotal Regional Dynamics Shaping Familial Adenomatous Polyposis Treatment Adoption in the Americas Europe Middle East Africa and Asia Pacific

Regional analysis underscores distinct adoption patterns and strategic priorities across the Americas, Europe Middle East Africa (EMEA) and Asia Pacific. In the Americas, robust research infrastructure and established reimbursement frameworks have supported early adoption of advanced endoscopic techniques and targeted biologic therapies. Leading academic centers in North America are spearheading clinical trials for gene editing approaches, while telemedicine initiatives in remote areas have improved surveillance outreach and adherence monitoring.

Within Europe, Middle East and Africa, treatment landscapes exhibit heterogeneity driven by national healthcare policies and resource availability. Western European nations have integrated precision therapeutics within standardized care pathways, whereas certain Middle Eastern and African markets are prioritizing capacity building for endoscopic services and pharmacologic accessibility. Cross-regional collaborations are emerging to harmonize regulatory guidelines, enabling streamlined approvals for innovative agents and equipment.

In the Asia Pacific region, rising awareness of hereditary colorectal disorders is fueling investment in diagnostic services and patient education programs. Governments are incentivizing local production of generic chemopreventive agents and facilitating technology transfer partnerships to enhance access. Infrastructure expansion in Southeast Asia has improved hospital pharmacy networks, while online platforms are increasingly utilized to bridge gaps in distribution. Specialty clinics in key urban centers are consolidating multidisciplinary care teams, reflecting a shift toward integrated management models.

Looking ahead, cross regional knowledge exchange and public private partnerships will be critical to harmonize standards of care and disseminate best practices, ensuring that innovations in FAP management deliver maximum patient benefit on a global scale.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Positioning within the Familial Adenomatous Polyposis Treatment Ecosystem

Industry participants within the FAP treatment landscape encompass a spectrum of biopharmaceutical innovators, medical device manufacturers and specialized service providers. Leading biotechs have advanced gene therapy candidates through early phase studies, harnessing viral and nonviral delivery vectors to target APC gene correction. Established pharmaceutical firms continue to optimize monoclonal antibody pipelines, focusing on novel epitopes that modulate Wnt signaling and reduce polyp burden. Nonselective and COX-2 selective NSAID developers are evaluating next generation formulations aimed at enhancing gastrointestinal tolerability and reducing systemic side effects.

Medical device companies are driving advancements in endoscopic hardware, introducing flexible platforms with integrated high resolution imaging, artificial intelligence assistance and accessory compatibility for streamlined polypectomies. Collaborations between diagnostic specialists and imaging software providers are yielding real time analytics that inform procedural decision making. On the distribution front, pharmacy networks and logistics partners are refining cold chain protocols to support the growing portfolio of temperature sensitive biologics and gene therapy products.

Strategic alliances between biopharma and academic centers are accelerating translational research, while partnerships with contract research organizations are expediting trial operations. Early stage companies have leveraged venture funding to validate proprietary delivery technologies, attracting attention from larger players seeking acquisition or licensing agreements. Furthermore, the pursuit of orphan drug designations and expedited regulatory pathways is incentivizing research investment, with several companies leveraging exclusivity provisions to support long term development programs. Intellectual property strategies and patent litigation trends will shape the competitive landscape as novel therapies progress toward commercialization.

Formulating Actionable Recommendations for Industry Leaders to Improve Access and Enhance Patient Outcomes in Familial Adenomatous Polyposis Treatment

To capitalize on emerging opportunities within the FAP treatment arena, industry leaders should prioritize investment in advanced gene editing platforms and companion diagnostics that enable precise patient stratification. Strengthening supply chain resilience through the development of domestic manufacturing capabilities or alternative sourcing agreements will mitigate the impact of external tariff pressures on critical equipment and reagents. Concurrently, establishing value based collaboration models with payers can align reimbursement incentives with patient outcomes rather than procedural volume, fostering sustainable adoption of high cost biologics and gene therapies.

It is essential to integrate digital health solutions into care pathways, leveraging remote monitoring tools and artificial intelligence driven decision support to enhance adherence, optimize surveillance schedules and reduce the burden on clinical resources. Partnerships with technology providers and data analytics firms can unlock real world evidence that informs continuous improvement and regulatory filings. Engagement with policymakers and industry associations should be intensified to advocate for balanced trade policies and streamlined approval processes, ensuring uninterrupted access to innovative treatments.

In parallel, developing risk management frameworks and scenario planning exercises will equip leadership teams to anticipate regulatory adjustments, tariff shifts and competitive moves. Investing in real time data platforms that offer predictive insights into patient volumes, therapy responses and operational bottlenecks will further enhance strategic resilience. Lastly, cultivating multidisciplinary care networks that unite gastroenterologists, genetic counselors, surgeons and allied health professionals will drive holistic patient management and improve quality of life outcomes.

Detailing the Rigorous Research Methodology of the Familial Adenomatous Polyposis Treatment Study Including Data Sources Frameworks and Validation Processes

The methodology underpinning this report combines comprehensive secondary and primary research to ensure the integrity and depth of insights. Secondary research involved an exhaustive review of peer reviewed literature, clinical guidelines published by leading gastroenterology and oncology societies, regulatory filings and patent databases. Market related intelligence was cross validated with policy analyses, trade reports and government publications to capture the broader economic and regulatory context.

Primary research incorporated structured interviews and surveys with key opinion leaders, including gastroenterologists specializing in hereditary colorectal disorders, surgical oncologists, clinical geneticists and supply chain experts. Additional discussions with hospital administrators, pharmacy directors and payer representatives provided practical perspectives on procurement challenges, reimbursement dynamics and patient access considerations. Data from these interactions were rigorously triangulated with secondary sources to resolve discrepancies and refine thematic conclusions.

An analytical framework guided segmentation by treatment type, route of administration, distribution channel, end user and indication, facilitating targeted insight generation. Regional analyses employed economic and healthcare infrastructure metrics to contextualize adoption patterns. Ethical oversight and patient consent protocols were carefully integrated into primary research activities, ensuring compliance with data privacy regulations and upholding participant confidentiality throughout the study process. Quality control measures included peer reviews by subject matter experts and systematic data verification to uphold factual accuracy. This robust approach ensures that the findings and recommendations reflect a balanced, evidence based understanding of the FAP treatment landscape.

Summarizing Strategic Insights into Familial Adenomatous Polyposis Treatment to Guide Stakeholders in Advancing Therapeutic Innovation and Patient Care

This executive summary distills the critical insights gleaned from a thorough examination of the familial adenomatous polyposis treatment domain. Advances in precision medicine, from gene editing breakthroughs to enhanced biologic and pharmacologic therapies, are revolutionizing clinical practice, while improvements in endoscopic technology and digital health integration are elevating detection, surveillance and patient engagement. The 2025 tariff landscape underscores the necessity of supply chain flexibility and strategic sourcing to preserve treatment affordability and continuity.

Segmentation analysis highlights the diverse modalities and delivery routes that shape tailored care pathways, as well as the pivotal role of distribution channels and end user environments in facilitating accessibility. Regional dynamics reveal a tapestry of healthcare ecosystems, each advancing FAP management in alignment with local priorities and resource capacities. Industry collaboration, characterized by partnerships between biotechs, device manufacturers and academic institutions, is accelerating translational research and fostering a competitive yet cooperative landscape.

Actionable recommendations emphasize the importance of investing in domestic manufacturing, value based contracting, digital platforms and multidisciplinary networks to drive sustainable innovation and enhance patient outcomes. Continuous monitoring of emerging clinical trial results and policy developments will be essential to maintain the relevance of these insights and to inform subsequent updates to the report. By applying these strategic imperatives, stakeholders across the healthcare continuum can navigate evolving challenges and deliver more effective, patient centered solutions for those affected by this hereditary condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emerging gene editing approaches for targeted suppression of APC mutations in familial adenomatous polyposis
  • 5.2. Advancements in endoscopic surveillance techniques for earlier polyp detection in FAP patients
  • 5.3. Clinical progression of combination therapy using COX-2 inhibitors and EGFR blockers in FAP management
  • 5.4. Regulatory impact of orphan drug designations on novel FAP treatment development pipelines
  • 5.5. Integration of predictive genetic profiling and personalized chemoprevention strategies in FAP care
  • 5.6. Expansion of minimally invasive colectomy procedures and postoperative quality of life outcomes research in FAP
  • 5.7. Emergence of biomarker-driven clinical trials evaluating targeted small molecule therapies in FAP cohorts
  • 5.8. Digital health monitoring platforms for real-time assessment of post-surgical recurrence risk in FAP patients
  • 5.9. Accessibility and adoption trends of next-generation NSAIDs for polyp burden reduction in global FAP markets
  • 5.10. Strategic partnerships between biotechs and academic centers accelerating translational research in FAP therapeutics

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Familial Adenomatous Polyposis Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Endoscopic Surveillance
    • 8.3.1. Colonoscopy
    • 8.3.2. Sigmoidoscopy
  • 8.4. Pharmacologic Therapy
    • 8.4.1. Biologics
      • 8.4.1.1. Gene Therapy
      • 8.4.1.2. Monoclonal Antibodies
    • 8.4.2. Nonsteroidal Anti-Inflammatory Drugs
      • 8.4.2.1. COX-2 Inhibitors
      • 8.4.2.2. Nonselective NSAIDs
  • 8.5. Surgical Intervention
    • 8.5.1. Colectomy
    • 8.5.2. Ileorectal Anastomosis
    • 8.5.3. Proctocolectomy

9. Familial Adenomatous Polyposis Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Familial Adenomatous Polyposis Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Familial Adenomatous Polyposis Treatment Market, by Indication

  • 12.1. Introduction
  • 12.2. Attenuated FAP
  • 12.3. Classic FAP

13. Americas Familial Adenomatous Polyposis Treatment Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Familial Adenomatous Polyposis Treatment Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eloxx Pharmaceuticals, Inc.
    • 16.3.2. Emtora Biosciences
    • 16.3.3. KD Pharma Group
    • 16.3.4. Biodexa Pharmaceuticals PLC
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. Olympus Corporation
    • 16.3.7. FUJIFILM Holdings Corporation
    • 16.3.8. Pentax Ricoh Imaging Company, Ltd.
    • 16.3.9. Medtronic plc
    • 16.3.10. Siemens Healthcare Private Limited
    • 16.3.11. Bayer Corporation
    • 16.3.12. Boston Scientific Corporation
    • 16.3.13. Parabilis Medicines

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 15. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 17. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 21. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 23. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHAI
  • FIGURE 26. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 28. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2024 (USD THOUSAND)
  • TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2025-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 32. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 34. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 36. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 38. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 40. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 42. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 44. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 46. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 48. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 50. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 52. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 54. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 56. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 58. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 60. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 62. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 64. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 66. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 68. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 70. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 72. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 74. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 76. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 78. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 80. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 81. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 82. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 83. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 84. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 85. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 86. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 87. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 88. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 89. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 90. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 91. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 92. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 93. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 94. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 95. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 96. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 97. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 98. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 99. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 100. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 101. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 102. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 103. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 104. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 105. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 106. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 107. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 108. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 109. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 110. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 111. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 112. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 113. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 114. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 115. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 116. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 117. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 118. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 119. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 120. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 121. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 122. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 123. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD THOUSAND)
  • TABLE 124. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD THOUSAND)
  • TABLE 125. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 126. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 127. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 128. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 129. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 130. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 131. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 132. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 133. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 134. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 135. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 136. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 137. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 138. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 139. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 140. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 141. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 142. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 143. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 144. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 145. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 146. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 147. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 148. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 149. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 150. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 151. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 152. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 153. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 154. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 155. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 156. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 157. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 158. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 159. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 160. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 161. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 162. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 163. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 164. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 165. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 166. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 167. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 168. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 169. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 170. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 171. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 172. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 173. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 174. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 175. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 176. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 177. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 178. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 179. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 180. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 181. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 182. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 183. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 184. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 185. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 186. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 187. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 188. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 189. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 190. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 191. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 192. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 193. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 194. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 195. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 196. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 197. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 198. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 199. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 200. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 201. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 202. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 203. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 204. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 227. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 228. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 229. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 230. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 231. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 232. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 233. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 234. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 235. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 236. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 237. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 238. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 239. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 240. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 241. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 242. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 243. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 244. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 245. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 246. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 247. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 248. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 249. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 250. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 251. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 252. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 253. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 254. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 255. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 256. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 257. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 258. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 259. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 260. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 261. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 262. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 263. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 264. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2